Sap Bakshi

Founder, Angel Investor and Senior Consultant (Pharma)

📍 Maidenhead, England, United Kingdom🔄 Updated October 2026💼 2 investments📅 8 years investing🗓 Last invested Jul 2019
VC🌍 United Kingdom
2
Total investments
0
Early stage
1
Mid stage
1
Late stage
8y
Years active

Portfolio

2 investments · sorted by recency
All investments
Early stage
Mid stage
Late stage
Angel Investor
Jul 2019
Arcis Biotechnology is focused on providing fast and convenient nucleic acid sample prep solutions. Obtaining genetic material from biological samples is a critical step which is often a time consuming and inefficient process. In less than 3 minutes with no prior sample preparation the Arcis DNA Prep range of products allow users to quickly and conveniently go from cellular material to downstream nucleic acid investigation without the need for traditional isolation or purification. The process requires no laboratory equipment and requires as little as 30µl of blood as a starting material. Arcis DNA products can be used on many different samples containing DNA including whole blood, plasma, urine, buccal swabs, and hair follicles and microbiological samples including bacteria (E. coli, S. aureus, P. aeruginosa, K. pneumoniae), viruses (HBV/ HCV) and parasites (plasmodium).
mid stageBiotechnology
Angel Investor
Sep 2018
Back pain is debilitating and limiting. It forces changes to the way people live and affects their quality of lie. Gelmetix addresses the most common cause of this critical problem through an efficient, cost effective and drug-free approach to preventing pain and restoring functionality and movement. Our patented polymer gel helps to restore the natural integrity of the disc itself. Injected directly, it rehydrates and stabilises, bringing back load-bearing properties and restoring the movement of the patient. Our polymer gel technology also has the potential to be adapted and extended for other uses. Gelmetix was founded in 2012, as a spin-off from the University of Manchester. In December 2020, Gelmetix was named “one of the most promising biotech start-ups in Europe” by EIT Health Catapult.
late stageMedical Device
Experience · 4 entries
All (4)
Investments (2)
Founder (1)
2019
Angel Investor
Jul 2019
Arcis Biotechnology is focused on providing fast and convenient nucleic acid sample prep solutions. Obtaining genetic material from biological samples is a critical step which is often a time consuming and inefficient process. In less than 3 minutes with no prior sample preparation the Arcis DNA Prep range of products allow users to quickly and conveniently go from cellular material to downstream nucleic acid investigation without the need for traditional isolation or purification. The process requires no laboratory equipment and requires as little as 30µl of blood as a starting material. Arcis DNA products can be used on many different samples containing DNA including whole blood, plasma, urine, buccal swabs, and hair follicles and microbiological samples including bacteria (E. coli, S. aureus, P. aeruginosa, K. pneumoniae), viruses (HBV/ HCV) and parasites (plasmodium).
mid stageBiotechnology
2018
Angel Investor
Sep 2018
Back pain is debilitating and limiting. It forces changes to the way people live and affects their quality of lie. Gelmetix addresses the most common cause of this critical problem through an efficient, cost effective and drug-free approach to preventing pain and restoring functionality and movement. Our patented polymer gel helps to restore the natural integrity of the disc itself. Injected directly, it rehydrates and stabilises, bringing back load-bearing properties and restoring the movement of the patient. Our polymer gel technology also has the potential to be adapted and extended for other uses. Gelmetix was founded in 2012, as a spin-off from the University of Manchester. In December 2020, Gelmetix was named “one of the most promising biotech start-ups in Europe” by EIT Health Catapult.
late stageMedical Device
2013
Prosper Property Solutions Ltd
Co-Founder
Mar 2013
2002
Various Global Pharma & Biopharmaceutical Clients
Senior Consultant
Jun 2002